Cart
sales@molnova.com
MyD88-IN-1
CAS No. 2911609-80-6
MyD88-IN-1( —— )
Catalog No. M36865 CAS No. 2911609-80-6
MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 164 | In Stock |
|
| 5MG | 150 | In Stock |
|
| 10MG | 225 | In Stock |
|
| 25MG | 373 | In Stock |
|
| 50MG | 454 | In Stock |
|
| 100MG | 646 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1330 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMyD88-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.
-
DescriptionMyD88-IN-1 is a potent MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor | NF-κB | MyD88 | TLR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2911609-80-6
-
Formula Weight528.54
-
Molecular FormulaC23H24N6O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (189.20 mM; Ultrasonic )
-
SMILESN(=O)(=O)C1=C(C=CC(S(NC=2C=CC(OC)=NC2)(=O)=O)=C1)N3CCN(CC4=CC(N(=O)=O)=CC=C4)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen P, et, al. Design, Synthesis, and Bioevaluation of Novel MyD88 Inhibitor c17 against Acute Lung Injury Derived from the Virtual Screen. J Med Chem. 2023 May 25;66(10):6938-6958.?
molnova catalog
related products
-
CP 424174
CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
-
Xeligekimab
Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.
-
Brodalumab
Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.
